Table 1.
Vaccination details for Australia, Finland, France, Norway and the United States, including the years of introduction, number of doses, surveillance data source, years of vaccination data available, and the serotyping performed.
| PCV introduction | Vaccine doses | Surveillance data source | Years of vaccination data available | Serotyping | |
|---|---|---|---|---|---|
| Australia |
PCV7: 2005 PCV10: 2009 (some jurisdictions) PCV13: 2011 |
3 + 0 | National Notifiable Disease Surveillance System (NNDSS) |
Pre-PCV7: 1999–2005 Pre-PCV13: 2006–2011 Post: 2012–2016 |
Quellung reaction, molecular serotyping |
| Finland |
PCV7: 2009 PCV10: 2010 |
2 + 1 | National Institute for Health and Welfare (THL) |
Pre-PCV10: 2004–2010 Post: 2011–2016 |
Quellung reaction |
| France |
PCV7: 2006 PCV13: 2010 |
2 + 1 | Centre National de References des Pneumocoques (CNRP) |
Pre-PCV7: 2001–2006 Pre-PCV13: 2007–2010 Post: 2011–2016 |
Fourier transformation-infrared spectroscopy, multi locus sequence typing, genomic sequencing |
| Norway |
PCV7: 2006 PCV13: 2011 |
2 + 1 | Meldesystem for Smittsomme Sykdommer (MSIS) |
Pre-PCV13: 2006–2011 Post: 2012–2016 |
Quellung reaction |
| USA |
PCV7: 2000 PCV13: 2010 |
3 + 1 | CDC’s Emerging Infections Program/Active Bacterial Core Surveillance |
Pre-PCV13: 2005–2010 Post: 2011–2013 |
Quellung reaction |
Data from the United States was taken from a published paper21.
PCV pneumococcal conjugate vaccine.